A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

NCT00500370 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of the medication exenatide on body weight in adults who are obese but do not have diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 163 people

Who can join Ages 18+ · all sexes

Timeline Started 2007-06 · est. completion 2008-02

Where 16 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT00500370 ↗

Description as written by the study sponsor.

This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects.

Treatments tested

exenatide also known as Byetta Drug

subcutaneous injection (5mcg or 10mcg), twice a day
placebo Drug

subcutaneous injection (equivalent volume to active dose), twice a day

Main thing measured	Change in Body Weight
Sponsor	AstraZeneca
Conditions studied	Obesity
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00500370 ↗